Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prophylactic Radiotherapy Optimization for Enhanced Thyroid Function Protection in Nasopharyngeal Carcinoma (PROTECT-NPC): A Multicenter, Non-Inferiority, Open-Label, Randomized Controlled Phase III Clinical Trial

NCT06752239 is registered in ClinicalTrials.gov with Jiangxi Provincial Cancer Hospital as lead sponsor.

NCT NCT06752239
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06752239 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prophylactic Radiotherapy Optimization for Enhanced Thyroid Function Protection in Nasopharyngeal Carcinoma (PROTECT-NPC): A Multicenter, Non-Inferiority, Open-Label, Randomized Controlled Phase III Clinical Trial
Lead sponsor
Jiangxi Provincial Cancer Hospital
Phase
Phase 3
Overall status
Recruiting
Start date
January 1, 2025
Completion date
December 31, 2031
Enrollment
474 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

nasopharyngeal carcinoma, quality of life, radiotherapy, radiotherapy side effect, thyroid diseases